ribociclib
novartis
['bcsm', 'natalee']
 natalee meets primary endpoint on second interim efficacy analysis, with 25% reduction in risk of idfs with absolute benefit of 3.3%. #asco23 #bcsm 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine